Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CEA loaded dendritic cell vaccines

Michael A Morse1, Timothy M Clay, H Kim Lyerly

  • 1Departments of Medicine and Surgery, Duke University Medical Center, P.O. Box 3233, Durham, NC 27710, USA. morse004@mc.duke.edu

Cancer Chemotherapy and Biological Response Modifiers
|April 22, 2003
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026
Same author

Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves.

Circulation. Cardiovascular interventions·2026
Same author

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications·2025
Same author

Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.

JACC. Cardiovascular interventions·2025
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles